ERBB2 and breast carcinoma: From a molecular point of view, the combination of trastuzumab and docetaxel downregulated HER2 and upregulated HSP90 protein expression selectively in HER2+ breast cancer cell lines (AU565, BT474 and MCF7-HER2) after 72h of treatment (Figure 2B and Figrue S2C).